BTL Industries v. Modifi Laser & Body Sculpting: EMSCULPT Patent Dispute Settles in 56 Days
BTL Industries, Inc., holder of US10478634B2 covering its EMSCULPT electromagnetic body-contouring platform, filed suit in the Southern District of Texas against Modifi Laser & Body Sculpting LLC for allegedly advertising competing services using BTL’s protected brand and device designations. The case resolved via consent judgment and a court-sealed settlement agreement in under two months.
EMSCULPT brand enforcement ends swiftly with sealed consent deal
On 18 March 2025, BTL Industries, Inc. filed a patent infringement action in the United States District Court for the Southern District of Texas against Modifi Laser & Body Sculpting LLC, a body-contouring clinic. The complaint centred on US10478634B2, a patent covering electromagnetic muscle-stimulation body-contouring technology marketed under the EMSCULPT and EMSCULPT NEO brands. BTL alleged that Modifi had advertised body-contouring services using BTL’s protected device designations — including EMSCULPT, EMSCULPT NEO, the BTL logo, and variations such as EMSCULPTOR NEO and HIEMS — without authorisation.
The case closed on 13 May 2025, just 56 days after filing, through a consent judgment — a court-entered resolution that typically reflects a negotiated agreement between both parties. Critically, the court granted BTL’s motion to file the settlement agreement under seal, meaning the specific financial terms, licensing provisions, and any injunctive commitments remain confidential. The consent judgment itself is the only public artefact of the resolution.
The rapid resolution is consistent with enforcement actions where the defendant lacks patent litigation resources or elects early settlement to avoid discovery costs and potential injunctive exposure. The sealing of the settlement agreement is commercially notable — it prevents competitors and other potential infringers from learning the precise terms BTL is willing to accept, preserving its enforcement leverage in future actions. What remains unknown is whether Modifi secured a licence to continue operations or agreed to cease use of the contested designations entirely.
Filing to Consent Judgment in 56 days
56 days — well below the median time-to-resolution for patent infringement cases in the S.D. Texas
Consent judgment and sealed settlement: what the record reveals
Consent judgment signals negotiated resolution, not contested ruling
A consent judgment is a court-entered order reflecting the parties’ own agreement rather than a judicial merits determination. It carries the legal force of a court order — making any breach enforceable as contempt — while keeping the underlying negotiated terms confidential if the settlement is filed under seal, as here. It is a common resolution mechanism in brand-enforcement and patent infringement cases where the defendant opts to settle rather than contest validity or non-infringement.
No merits adjudicationSealed agreement preserves BTL’s enforcement posture
The court’s grant of BTL’s motion to seal the settlement agreement means no financial figures, licensing royalties, or injunctive terms are publicly available. This is strategically significant for BTL: it prevents other aesthetic clinics from using the disclosed terms as a benchmark when evaluating whether to contest or settle similar demands. For Modifi, the seal also protects any reputational or commercial sensitivity. The public record discloses only that a settlement was reached — not its content.
Terms undisclosedEarly settlement avoids validity challenge and injunctive risk
Modifi’s decision to settle within 56 days — before any substantive motion practice or claim construction — is consistent with a small operator calculating that litigation costs and the risk of a permanent injunction on core business operations outweigh the cost of settlement. No defendant counsel is listed on the public docket, suggesting Modifi may have engaged in settlement negotiations directly or through newly retained counsel not yet formally entered in the case.
No defendant counsel on recordRapid enforcement signals active BTL brand and patent policing strategy
BTL’s willingness to file federal litigation and pursue sealed consent judgments — rather than demand letters alone — signals a structured enforcement programme against clinics advertising EMSCULPT services without authorisation. Aesthetic service providers using any variation of the EMSCULPT designation or referencing BTL device platforms in their marketing should treat this outcome as a material infringement risk indicator, particularly if operating outside a formal BTL distributor or licensing arrangement.
Active enforcement programme likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BTL Industries, Inc. | Company | Medical aesthetics device manufacturer — holder of US10478634B2 (EMSCULPT body-contouring platform)Search in Eureka ↗ |
| Defendant | Modifi Laser & Body Sculpting LLC | Company | Body-contouring clinic alleged to have advertised services using BTL’s protected EMSCULPT designationsSearch in Eureka ↗ |
| Plaintiff counsel | Michael Dru Montgomery | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Heartfield Law Firm | Law Firm | Representing BTL Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Alfred H Bennett | Judge | Texas Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is purely procedural — it grants BTL’s motion to seal the settlement agreement rather than adjudicating infringement or validity on the merits. The underlying consent judgment signals that both parties agreed to a resolution, but the operative terms of that agreement are withheld from public view. The phrasing ‘shall remain under seal’ indicates an indefinite confidentiality order, meaning the settlement terms are unlikely to become available through routine docket monitoring. The verdict cause of ‘Infringement Action’ reflects the original claim framing; it does not represent a judicial finding of infringement.
US10478634B2 — Electromagnetic body-contouring and muscle-stimulation device
US10478634B2, filed under application number US16/034793, protects technology at the core of BTL’s EMSCULPT platform — a non-invasive body-contouring system that uses high-intensity focused electromagnetic energy to induce supramaximal muscle contractions, simultaneously reducing adipose tissue and building muscle mass. The patent covers the device architecture, energy delivery methodology, and treatment protocols that underpin both EMSCULPT and the subsequent EMSCULPT NEO system, which adds radiofrequency energy to the electromagnetic stimulation cycle.
In the competitive medical aesthetics device market, US10478634B2 represents a significant enforcement asset for BTL. The EMSCULPT platform competes against a growing field of body-contouring modalities including cryolipolysis, laser lipolysis, and radiofrequency-alone devices. By asserting this patent not only against device manufacturers but against clinics advertising services using the EMSCULPT designation — even in misspelled or variant form — BTL is effectively deploying the patent to police downstream distribution and service delivery, a strategy that substantially extends the patent’s commercial reach beyond OEM competition.
Should you run an FTO against US10478634B2?
Any company developing, manufacturing, or marketing an electromagnetic muscle-stimulation body-contouring device should treat US10478634B2 as a priority FTO target. This case also signals that aesthetic clinics advertising services with EMSCULPT-adjacent branding — including HIEMS or NEO-suffix identifiers — may face infringement exposure under BTL’s enforcement programme, even absent device manufacturing activity. R&D teams developing competing HIFEM or combined RF-HIFEM platforms should audit claim scope before finalising product specifications or marketing materials.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claims of US10478634B2 against your device architecture, energy delivery specifications, and treatment protocols to identify overlap risk. Eureka can also surface the broader BTL patent family, identify prosecution history estoppel boundaries, and flag prior art that may support design-around strategies — giving your IP and product teams actionable clearance intelligence before market entry.
Run a freedom-to-operate analysis on US10478634B2 to assess your product’s exposure
Run FTO in Eureka →Similar EMSCULPT and body-contouring patent enforcement cases
Explore related electromagnetic body-contouring and medical aesthetics patent infringement cases filed in U.S. district courts against device makers and service providers.
What this case signals for the medical aesthetics IP landscape
BTL’s swift, sealed resolution against a small clinic reveals a scalable enforcement model that aesthetic device competitors and service providers should monitor closely.
Federal litigation is BTL’s enforcement tool of choice for brand misuse
Rather than relying solely on cease-and-desist letters, BTL filed in federal court and secured a consent judgment in under two months. This suggests a structured, repeatable enforcement playbook. Competing device manufacturers and aesthetic clinics referencing EMSCULPT in service advertising — even informally — face material litigation exposure under US10478634B2.
Sealed settlements preserve asymmetric leverage for patent holders
The court-sealed settlement prevents market participants from reverse-engineering BTL’s settlement floor. For IP practitioners advising aesthetic clinics or competing device makers, this means standard benchmarking against prior settlements is unavailable — each enforcement target must independently assess litigation risk without public comparables from this case.
BTL v Modifi — key questions answered
BTL Industries asserted US10478634B2, filed under application US16/034793, covering electromagnetic muscle-stimulation body-contouring technology at the core of the EMSCULPT and EMSCULPT NEO platforms. The patent protects the device architecture and treatment protocols enabling high-intensity focused electromagnetic body contouring.
The case was resolved by consent judgment — a court-entered order reflecting a negotiated agreement between the parties — on 13 May 2025, just 56 days after filing. The court also granted BTL’s motion to file the settlement agreement under seal, meaning the financial and operational terms of the resolution are not publicly available.
BTL alleged that Modifi Laser & Body Sculpting advertised body-contouring services using protected designations including EMSCULPT, EMSCULPT NEO, the BTL logo, EMSCULPTOR, EMCULPTOR NEO, UMSCULPTOR NEO, and HIEMS without authorisation. The complaint covered both direct brand use and phonetically similar variant designations.
A sealed settlement means the court has ordered the settlement agreement to remain confidential and unavailable on the public docket. In this case, the consent judgment itself is publicly recorded, confirming the case resolved by agreement, but the specific financial terms, any licensing provisions, and injunctive obligations are withheld. This prevents third parties from using the disclosed terms as a benchmark in future negotiations with BTL.
This case suggests aesthetic clinics advertising body-contouring services with EMSCULPT-adjacent designations — including HIEMS and NEO-suffix variants — may face enforcement action under US10478634B2 and related BTL IP. BTL’s rapid pursuit of a federal consent judgment against a small clinic operator is consistent with a scalable enforcement programme. Clinics should verify they are operating under a legitimate BTL distributor or licensing arrangement before referencing these designations in advertising.
PatSnap Eureka searches patents and litigation data to answer instantly.